Lupin went from losing money to a 29% margin in four years, a genuine turnaround. The catch: a good chunk of that margin is US exclusivity money, and exclusivities expire.
Lupin is an Indian pharmaceutical company. It makes generic and speciality medicines, earning most of its profit from harder-to-make drugs and early regulatory filings, and sells heavily into the United States and India.
Sector
Healthcare · Pharmaceuticals
Founded
1968
Head office
Mumbai
Revenue (FY26)
₹27,958 cr
Market cap
₹1,10,422 cr
Promoter holding
46.85%
Fathom view
Business
Real turnaround
Moat
Narrow
Margin quality
Peak, exclusivity-fed
Balance sheet
Low debt
Valuation
~19x on peak margin
Key questionThe turnaround is real. How much of the 29% margin is US exclusivity money that expires?
Lupin's real product is not the pill. It is being first, and being able to make what rivals cannot.
When a drug patent expires, the health system wants a cheap copy, but plenty of factories can make the easy ones and the price crashes fast. The ones worth having are the hard copies, the drugs few rivals can manufacture and get past the regulator. Lupin earns its place when it can make those, file them cleverly, and sell trusted branded medicines back home in India.
Why has no one else already won? Because every profit pool in generics drains itself. A rival gets approved, the price falls, a regulator flags a plant, and the money you made last year is gone. To stand still, Lupin has to keep refilling the pipeline with the next hard drug. Stop, and the margin slides back to commodity levels.
The economic engine
Demand
Prescriptions and patent expiries
Chronic demand at home plus global generic opportunities.
Revenue
India brands + US launches
India gives steadier repeat revenue; the US adds lumpy upside.
Margins
Complexity and exclusivity
Margins rise when fewer competitors can make the product.
Capital
R&D, filings and plants
The company must keep spending to replace products that fade.
Returns
Peak ROE if pipeline works
Returns stay high only if new complex launches replace old windfalls.
Mental model heatmap
★★★★★
Regulation
Plant approvals and clean inspections decide which products can ship.
★★★★★
Complexity
Harder products attract fewer competitors and better margins.
India branded generics are stickier than plain US generics.
★★★★★
Pipeline Renewal
The company must replace fading products with new launches.
Strategic position
Plain generic manufacturers
Compete mostly on price; margins erode fastest.
↓
Lupin
Turnaround player moving into complex generics with an India branded base.
↓
Best-in-class pharma compounders
Broader specialty, branded or complex pipelines with more durable margins.
Why now
The turnaround is no longer a story, it is in the numbers: high margins, real cash, a fixed US business. That is exactly why it is worth a look now, and also why the argument is live. Is this the new floor for earnings, or a peak propped up by exclusivity wins that will not repeat? Everything hangs on that one question.
Current margins do not collapse back to commodity-generic levels.
Why the business works
The US business has been repaired after years of weak execution.
Complex generics and first-to-file launches have lifted margins sharply.
India branded generics provide a sticky, higher-quality earnings base.
Cash flow now supports the turnaround rather than contradicting it.
Why the thesis could fail
US exclusivity products fade as competitors enter and prices erode.
Regulatory observations or plant issues can delay launches and damage credibility.
A weak pipeline would expose the difference between peak margin and normal margin.
Plain generic price erosion can offset gains from new launches.
Sector mental models
Pricing Power
Mixed
Weak in plain US generics, stronger in complex products and India brands.
Regulatory Risk
High
Plant compliance is central to the business model.
Operating Leverage
High at peaks
A successful launch can lift margins quickly.
Durability
Uneven
Some profits are recurring; some are launch windfalls.
Capital Intensity
Medium
R&D, filings and specialised manufacturing keep the engine alive.
One sentence to remember
A real turnaround, with a catch worth memorising: some of this profit expires on a schedule, and it only deserves a permanent price once Lupin proves it can keep replacing it.
01Company Overview
Lupin makes medicines, but that is not really where its money comes from. A plain generic drug is a race to the bottom: the day enough factories can make it, the price collapses and nobody earns much. The profit shows up somewhere else, in the short stretch when Lupin can do something the crowd cannot yet. File a drug first, make something genuinely hard to manufacture, pass the regulators, and for a while you are the only generic on the shelf, like the one shop selling umbrellas the week it rains. That window is where the fat margins live. Lupin has spent its turnaround moving toward exactly this kind of product, complex generics and respiratory drugs, with a steady India branded business underneath for ballast. The numbers today are dazzling. The real question is how much of the profit keeps coming once the rain stops.
Long-established Mumbai pharma house, listed for decades. No repackaging games.
02Business Model & Industry
Unit of revenue: A pack of medicine sold. At home in India it goes out under a brand a doctor trusts, at a healthy margin. In the US it goes out as a generic, where the price drops a little every year unless the drug is genuinely hard to make or Lupin holds an exclusivity on it.
Model: Two markets from its own factories. In India it sells branded generics that doctors prescribe by name. Abroad, chiefly the US, it sells generics, some plain and cheap to copy, some complex and hard, and the hard ones are where the real money sits.
US formulations40%
High right now, boosted by exclusivities that fade
India branded35%
Steady, high-quality, sticky
EM / EU / API / other25%
Mixed, provides diversification
Structure
Fragmented globally. In US generics, whoever is cheapest wins, so it is close to commoditised except for complex products; in India, branded loyalty softens the competition.
Competitors
Sun Pharma, Dr Reddy's, Cipla, Aurobindo, plus global generic majors in the US.
Pricing power
Weak on plain US generics (price only erodes), genuine on complex products and on India branded medicines.
Demand driver
Chronic-illness prescriptions at home, and a steady stream of US patent expiries that open up generic opportunities abroad. (Structural (rising healthcare demand, ageing populations) with a lumpy overlay from individual product launches and exclusivities.)
TAM
A very large global generics and complex-generics market, but one where price erosion means you must keep launching just to stand still.
Penetration
Mature in plain generics; the growth is in harder complex generics, biosimilars and respiratory where fewer rivals can compete.
Value-chain seat
Manufacturer and marketer. The margin lives in complexity and brand, not in the plain molecule.
Is it well run? Now, yes. The business is genuinely healthier than it was, the push into complex generics and respiratory drugs is the right strategy, and the India franchise is a solid base that does not swing around. But be honest about the headline. That 29% margin is a peak, lifted by first-to-file wins like Tolvaptan, and a first-to-file win is a jackpot, not a salary. So you are looking at a good company caught at a flattering moment. The durable core underneath is real. The number on top is partly borrowed from wins that do not come around again.
03Valuation Snapshot
Market Cap
₹1,10,422 cr
52W High / Low
₹2,530 / ₹1,837
Stock P/E
19.4
mcap / profit ≈ 20.6
P/B
4.92
EPS (TTM)
₹116.65
Book Value
₹491
04Financial Performance (5Y, in Crores)
FY22
₹16,405net ₹-1,528 · -9.3%
FY23
₹16,642net ₹448 · 2.7%
FY24
₹20,011net ₹1,936 · 9.7%
FY25
₹22,708net ₹3,306 · 14.6%
FY26
₹27,958net ₹5,355 · 19.2%
RevenueNet profit₹ crore · % = PAT margin
05Key Ratios
ROE
28.7%
ROCE
29.9%
OPM
~29%
peak, exclusivity-boosted
PAT Margin
~19.2%
P/B
4.92
Profit CAGR 3Y
140%
off a FY22 loss, ignore this
06Cash Flow Forensics (in Crores)
FY24
OCF₹3,648Capex₹1,712FCF₹1,936
FY25
OCF₹3,000Capex₹4,172FCF₹-1,172
FY26
OCF₹7,334Capex₹3,865FCF₹3,469
Here is the reassuring part, and it matters when a margin has moved this fast. The cash backs the profit. Operating cash flow jumped to ₹7,334cr in FY26, comfortably more than reported profit, so this is not a paper turnaround dressed up in accounting. Capex has been heavy, because Lupin is building complex-generics and respiratory capacity, and that briefly pushed FY25 free cash flow below zero. That is money going into the next set of products, not leaking out. By FY26 free cash flow was solidly positive again.
07Growth
Sales CAGR 5Y
13%
Sales CAGR 3Y
19%
Profit CAGR 3Y
140%
meaningless, FY22 was a loss
Stock CAGR 1Y
29%
Stock CAGR 5Y
16%
08Management
Promoter-led by the Gupta family, who hold 46.85%, with Vinita and Nilesh Gupta running it. Credit where it is due. This is the team that actually turned the business around: fixed the broken US operation, pointed the pipeline at harder products, and rebuilt both the margin and the market's trust. They funded the push from the company's own cash instead of repeatedly asking shareholders for more, which is the disciplined way to do it. The test in front of them is the same one the whole thesis rests on. Can they replace the exclusivity money as it fades with durable earnings from complex drugs?
The moat is narrow but real, and it lives in the products rivals struggle to copy: complex generics, inhalers and biosimilars, plus a sticky India brand book that keeps prescribing itself. It is not wide. The plain generics have no moat at all, and one bad factory inspection can hurt fast. Whether the moat holds comes down to a single race: can Lupin launch new hard drugs faster than its current winners fade? That is the whole job.
11The Story So Far
Rewind to FY22 and Lupin was the problem child of big Indian pharma: a loss on the books, a broken US business, and a market that had stopped believing. What came next was a real turnaround. Management cleaned up the factories, pivoted toward complex generics, and caught a couple of big US breaks, the biggest being the first-to-file launch of generic Tolvaptan with six months where it was effectively the only seller. Margins climbed from barely positive to 29%, the loss turned into profit above ₹5,000cr, and the stock rerated with it, up 29% in the last year alone. The bull case is that the complex-generics and respiratory pipeline keeps this going. The bear case is simpler: a slice of today's profit is rain that stops. When those exclusivity windows shut, does anything refill them?
12Risks
Exclusivity roll-off. A meaningful slice of the current margin comes from time-limited first-to-file products like Tolvaptan. As those windows close, profit can step down even if the business is fine. Medium-High.
US price erosion. The plain-generics part of the US book keeps eroding, so Lupin must keep launching complex products just to hold ground. Medium.
Factory risk. Like any Indian pharma, a bad USFDA inspection at a key plant could freeze a chunk of the US pipeline overnight. Medium.
Peak-margin extrapolation. If the market treats 29% margins as the new normal, disappointment is easy to trigger. Medium.
Pipeline execution. The whole thesis rests on complex generics and respiratory launches arriving on time and at scale. Medium.
13What the Headline Numbers Hide
✓ clean! caution✕ red flag– n/a
✓
Profit backed by cash
OCF ₹7,334cr exceeds profit
!
Growth on a trough base
140% profit CAGR is off a FY22 loss, meaningless
!
Peak-margin risk
29% margin flattered by exclusivities
✓
Promoter pledging
No pledge
!
Regulatory / factory risk
USFDA action is an ever-present pharma risk
✓
Stretched multiple
~20x is fair, not demanding
Sector checklist
✓
Domestic chronic growth
Steady, high-quality India branded base
✓
Pipeline quality (complex, not just count)
Complex generics, inhalation, biosimilars
!
Factory track record
Improved, but always a live risk
!
One-off vs run-rate profit
Margin boosted by fading first-to-file wins
14Two-Engine Assessment
Earnings engine
The earnings engine has been extraordinary, and you have to separate why. Part is genuine: complex generics, a repaired US business, a steady India base. Part is the exclusivity windfalls that expire. Strip out the windfalls and the durable growth is real but ordinary, probably mid-teens. The recent explosive pace is not something you can pencil in again. The forward catalysts are concrete but lumpy, arriving whenever a new complex, respiratory or biosimilar product actually launches, not on a neat schedule.
Multiple engine
At around 20 times earnings, the multiple is fair, not stretched. It already climbed as the turnaround proved itself, so the easy re-rating is behind you. The trap here is quiet. If earnings are near a peak, then even an unchanged multiple on a profit that steps down leaves the stock going nowhere. The price does not have to fall for you to make nothing.
So here is my honest read. The earnings engine is strong, but part of it is borrowed from exclusivities, and the multiple has already done its re-rating. Put those together and almost everything rides on one thing: can Lupin keep replacing the fading windfalls with durable profit from hard-to-make drugs? I think the management has earned enough trust to give them the benefit of the doubt on execution. What I cannot tell you is the timing, whether the next batch of complex launches lands before the current exclusivities roll off or after. That gap, if it opens, is where a good business has a dull year. Judge this one on the lower, durable margin, not the flattering peak, and you will not be surprised.
15Mental-Model Lenses
The first-to-file jackpot
Tolvaptan and drugs like it pay for six months, then stop. They are windfalls, not a salary. Treat a quarter fattened by one as the new normal and you will pay up right before the window slams shut. This is the oldest trap in pharma, and it catches people every cycle.
Operator vs storyteller
Plenty of pharma bosses can describe a brilliant pipeline. This management actually repaired the US business and the margins first, then talked about it. That is the difference between evidence and a slideshow, and it is why their pipeline promises are worth more than most.
Foreshock
There is no slowdown to point at yet, quite the opposite. That is what makes the risk here sneaky. It is not a loud crack in the results. It is a quiet step-down in the margin the quarter an exclusivity expires and nothing new has replaced it. Watch the segment margin over the next few quarters, not the headline.
Convergence pair
Line Lupin up against Sun Pharma and Dr Reddy's and it looks cheaper on trailing earnings. Ask why before you get excited. The market is not being sloppy. It suspects those earnings are near a top, so the discount may be a fair judgement rather than a mistake waiting to be corrected.
16Outlook: What Happens Next?
The turnaround itself is settled. Lupin went from a FY22 loss to running a roughly 30% margin. What is not settled is what that margin really is: a durable base, or a peak inflated by US exclusivities that fade. This section does not try to guess the answer. It walks through what has actually happened in each part of the business, and then hands you the one question to watch in each. All the figures below are from the Q1 FY27 results, the quarter ended June 2026.
01
The core margin
The EBITDA margin was about 30% in Q1 FY27, up from 26.6% a year ago, and gross margin rose to 74.6% from 71.3%.
EBITDA grew roughly 50% on revenue that grew 32%, so the operating leverage is real, not just a flattering mix.
But net profit margin slipped to 17.2% from 19.8%, and PAT grew only 16% against that 50% at the EBITDA line. The gap opens up below EBITDA (tax, depreciation and a tough year-ago base), not in the operating business itself.
What to watchIs the ~30% EBITDA margin the durable base, or a peak that fades as US exclusivities roll off? Watch the segment margin, not the record headline revenue.
02
The US exclusivity engine
US sales were $366 million, up 30% year on year but actually down 1% on the previous quarter, from $371 million.
Management was blunt about why: the base kept growing, but more competition and the loss of exclusivity on some products ate the gain. Mirabegron, for instance, is seeing a mid-single-digit price decline as rivals pile in.
The US is 42% of global sales. Lupin sells 149 generic products there, added 6 ANDA approvals and launched 3 in the quarter, and is sitting on 50 first-to-file positions, 21 of them exclusive.
What to watchDo new complex launches replace the fading exclusivity profits fast enough to keep the US book growing, rather than just holding it flat?
03
The India and rest-of-world base
India formulations grew 14% year on year to Rs 2,380 cr, with anti-diabetes up 31.8%, well ahead of the overall market.
The geographies outside the US and India are the fastest growing of all right now: EMEA up 37%, emerging markets up 52%, LATAM up 71%.
India is 29% of sales, and it is the steady kind: branded, repeat prescriptions that do not lurch around with US exclusivity windows.
What to watchDoes this steadier base grow fast enough to cushion the lumpy US exclusivity cycle when a big window closes?
04
The factory question
Lupin's Pithampur Unit II carries a USFDA OAI (Official Action Indicated) tag, with the fixes in progress.
The rest of the machine kept clearing regulators: a Ranibizumab biosimilar approval and 6 ANDA approvals landed this quarter.
And it could take a knock: net cash of about Rs 2,831 cr means net debt is actually negative.
What to watchDoes the Pithampur OAI get cleared, or escalate to a warning letter that freezes part of the US pipeline? In pharma this is the fastest way a good quarter turns bad.
05
The valuation question
The stock trades around 20x earnings, after the turnaround already did its re-rating.
Those earnings are near a peak partly built on exclusivities, so even a fair multiple on a profit that normalises can leave the stock drifting sideways.
Next to Sun Pharma and Dr Reddy's, Lupin looks cheaper on trailing earnings, but partly because the market suspects those earnings are near a top.
What to watchDoes durable, complex-product profit grow fast enough to offset the exclusivity roll-off, so the market stops treating the current margin as a peak?
Engines loaded, not yet in the P&L
Capacity already won or acquired, but not yet showing up in reported earnings.
Ranibizumab biosimilar (Ranluspec)FY27-28
A US FDA-approved biosimilar to Lucentis, and the first real product out of Lupin's home-grown biosimilars platform.
The approval is in hand, but the money only starts when it launches and takes share, not the day the FDA says yes.
Respiratory pipelineFY27 onward
Over 45 injectables and 20+ inhalation products (MDIs, DPIs, soft-mist inhalers, nasal sprays), the hard-to-copy formats where margins hold up.
Most are still being filed or developed, and only the ones that actually launch earn anything.
Exclusive first-to-file basketLumpy, FY27-29
21 exclusive first-to-file positions, each one a possible six-month margin window the day it launches.
Filed, not launched. The profit only shows up when a window actually opens.
GLP-1 opportunityBeyond FY28
The weight-loss and diabetes drugs everyone is chasing, which Lupin plans to go after both in-house and through licensing.
The earliest-stage of the four. Lupin has stated the intent, but there is no product and no revenue yet.
The next few quarters should start answering these. Keep your eye on the margin and the pace of the US exclusivity roll-off, not the record-looking revenue line at the top.
17Summary
Pull it together. Lupin is a real turnaround, run well, and the strategy of chasing harder complex generics on top of a steady India franchise is exactly right for an Indian pharma company. Two things keep it from being a clean story. The headline 29% margin is a peak, puffed up by US exclusivity wins that pay once and expire, so the earnings power you can actually rely on is lower than the trailing figures suggest. And at roughly 20 times earnings, the price already knows most of the good news. The honest way to hold this in your head is to judge it on its durable, lower margin and let the exclusivities be a bonus, not the base. Do that, and the next few quarters teach you rather than shock you.